Observational analysis reveals challenges in natural killer cell therapies for cancer, indicating collaboration may enhance clinical outcomes.
NK cell-based therapies represent a promising avenue in cancer immunotherapy but require carefully designed solutions to overcome their inherent limitations. Advances in biomarker-guided patient selection, integration with existing treatment modalities, and international collaboration will be critical for translating NK cell biology into effective and durable clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Aljabali et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: